Selective targeting of melanoma using N-(2-diethylaminoethyl) 4-[18F]fluoroethoxy benzamide (4-[18F]FEBZA): a novel PET imaging probe
© The Author(s). 2017
Received: 19 April 2017
Accepted: 25 July 2017
Published: 8 August 2017
The purpose of this study was to develop a positron emission tomography (PET) imaging probe that is easy to synthesize and selectively targets melanoma in vivo. Herein, we report the synthesis and preclinical evaluation of N-(2-diethylaminoethyl) 4-[18F]Fluoroethoxy benzamide (4-[18F]FEBZA).
A one-step synthesis was developed to prepare 4-[18F]FEBZA in high radiochemical yields and specific activity. The binding affinity, the in vitro binding, and internalization studies were performed using B16F1 melanoma cell line. The biodistribution studies were performed in C57BL/6 normal mice, C57BL/6 mice bearing B16F1 melanoma tumor xenografts, and nu/nu athymic mice bearing HT-29 human adenocarcinoma tumor and C-32 amelanotic melanoma tumor xenografts. MicroPET studies were performed in mice bearing B16F1 and HT-29 tumor xenografts.
4-[18F]FEBZA was prepared in 53 ± 14% radiochemical yields and a specific activity of 8.7 ± 1.1 Ci/μmol. The overall synthesis time for 4-[18F]FEBZA was 54 ± 7 min. The in vitro binding to B16F1 cells was 60.03 ± 0.48% after 1 h incubation at 37 °C. The in vivo biodistribution studies show a rapid and high uptake of F-18 in B16F1 tumor with 8.66 ± 1.02%IA/g in this tumor at 1 h. In contrast, the uptake at 1 h in HT-29 colorectal adenocarcinoma and C-32 amelanotic melanoma tumors was significantly lower with 3.68 ± 0.47%IA/g and 3.91 ± 0.23%IA/g in HT-29 and C-32 tumors, respectively. On microPET images, the melanoma tumor was clearly visible by 10 min post-injection and the intensity in the tumor continued to increase with time. In contrast, the HT-29 tumor was not visible on the microPET scans.
A rapid and facile synthesis of 4-[18F]FEBZA is developed. This method offers a reliable production of 4-[18F]FEBZA in high radiochemical yields and specific activity. A high binding affinity to melanoma cells and high uptake in tumor was noted. The microPET scan clearly delineates the melanoma tumor by 10 min post-injection. The results from these preclinical studies support the potential of 4-[18F]FEBZA as an effective probe to image melanoma.
KeywordsMelanoma 4-[18F]FEBZA Radiochemical synthesis Radiofluorination Binding affinity Cell binding Biodistribution MicroPET imaging
An estimated 87,000 new cases of melanoma of the skin will be diagnosed in the USA in 2017, and approximately 9730 individuals are anticipated to die of melanoma this year . Among many factors, lacking monthly self-inspection of the skin by patients, routine visits to the dermatologist combined with lack of effective diagnostic tools training for the accurate detection of melanoma at an early stage, malignant melanoma remains a significant health problem and remains as the sixth most prevalent type of cancer . While melanoma accounts for a small percentage of all skin cancer cases, 75% of deaths from skin cancer are associated with melanoma. Among many factors, late diagnosis and poor localization of metastatic lesions in patients with melanoma results in high mortality from this cancer . If diagnosed at stage 1 of this disease, the overall 10-year survival for melanoma patients is ~95%. By contrast, if this disease is diagnosed at stage IV, the overall survival drops to 10–15% . Therefore, early diagnosis and accurate assessment of metastatic lesions is crucial for appropriate treatment planning, improved outcome, and disease-free survival .
Positron Emission Tomography (PET) is a powerful tool to non-invasively study organ function and related disorders such as tissue perfusion and metabolism in vivo . PET imaging with F-18 fluorodeoxy glucose (FDG) has shown high sensitivity and specificity in the diagnosis and staging of various cancers  primarily due to its significantly higher uptake in malignant cells with elevated metabolic activity . While quite effective in many types of cancers, FDG-PET has shown a low mean sensitivity of 17.3% for detecting small lymph node metastases in patients with early-stage melanoma cancer [6–8], thus offering limited value in the initial staging of AJCC (American Joint Commission on Cancer) stage I, or stage II melanoma [6, 9, 10]. In another study, FDG-PET failed to detect melanoma in all 14 patients showing a positive sentinel lymph node biopsy for cancer . Additionally, the high uptake of FDG in brain tissues further limits its utility in detecting brain metastases . Therefore, developing a PET probe with high specificity and selectivity for melanoma and a low uptake in normal tissues has been the goal of many investigators [13–15].
To selectively target melanoma, the role of F-18- and Cu-64 labeled α–melanocyte-stimulating hormone analog to image melanoma by targeting melanocortin-1 receptors was evaluated [16–19] but showed limited success. In addition, potential of various fluorinated iodoquinoxaline carboxamide was also explored as imaging and therapeutic probe to target melanoma . Additionally, the efforts were made to develop radioiodinated benzamides as potential melanoma-targeting agents [21–24], partially inspired from the incidental finding of a high uptake of iodo-benzamides in uveal tissues of pigmented experimental animals . With the wider acceptance of PET as a clinical diagnostic tool for accurate diagnosis as well as encouraging findings on the ability of radioiodobenzamide to target melanoma, there has been a significant impetus to develop PET probes which incorporate benzamide moiety [17, 20, 25–30]. One such compound, 18F-DAFBA, which was initially reported by our group  and subsequently explored by other investigators, showed promising results . Nonetheless, the synthesis of DAFBA requires ~3 h and includes two or more high-performance liquid chromatography (HPLC) purifications . To overcome that hurdle, we subsequently developed 11C-MBZA with a shorter and easier synthesis . Preclinical evaluations of this 11C-probe showed superior in vitro and in vivo properties compared to that for 18F-DAFBA. While 11C-MBZA has many desirable features and properties, it incorporates a short half-life radionuclide (T 1/2 = 20 min). Therefore, we focused our efforts towards developing an F-18 benzamide with a short and facile radiochemical synthesis akin to 11C-MBZA while bearing similar or better biological properties. Herein, we report the synthesis, radiochemistry, and preclinical evaluation of 4-[18F]FEBZA as a PET probe to selectively and non-invasively target melanoma.
All chemicals were purchased from Sigma (Sigma-Aldrich, Milwaukee, WI) and were used without further purification. C-18 plus Sep-Pak cartridges were obtained from the Waters Corporation (Waters Corporation, Milford, MA). Flash column chromatography was carried out over silica gel (60 Å, Mallinckrodt Baker). HPLC was performed in the isocratic mode using an HPLC system (Varian Corp, Palo Alto, CA) equipped with an LC pump, a variable wavelength UV/VIS detector set at 254 nm, and an in-line radioisotope detector (Bioscan Inc., Washington, DC). The HPLC column for the purification of 4-[18F]FEBZA was a C-18 reverse-phase, 10 mm × 250 mm, 5-μ Luna column (Phenomenex, Torrence, CA), and elution was performed at a flow rate of 2 mL/min using a solution of methanol:0.1 M ammonium acetate (50:50) containing trimethylamine (40 μL/100 mL). The quality of the purified product was checked using a C-18 column (4.6 mm × 250 mm, 5 μ), eluted at a flow rate of 1 mL/min using methanol:0.1 M ammonium acetate (50:50) containing trimethylamine (40 μL/100 mL). 18F-Fluoride was produced by the 18O(p,n)18F nuclear reaction using O-18 enriched water (95% enrichment) on a GE PET-Trace 800 series cyclotron (GE Healthcare, Milwaukee, WI). Kryptofix solution was prepared by dissolving 120 mg of K2.2.2. and 720 mg of K2CO3 in 720 μL of water followed by the addition of 12 mL of acetonitrile. The accell plus QMA-cartridge was activated by successively flushing it with 5 mL of 1 N sodium bicarbonate solution and 10 mL of sterile water, followed by air flushing. The C-18 plus cartridge was activated by washing with 5 mL of ethanol followed by 10 mL of sterile water.
B16F1 melanoma cells, HT-29 human colorectal adenocarcinoma cells, and C-32 amelanotic melanoma cells were purchased from the American Type Culture Collection (ATCC, Rockville, MD). B16F1 murine melanotic melanoma cells were maintained in Dulbecco’s modified Eagles medium supplemented with 10% fetal calf-serum, 2 mM L-glutamine, and 1 mM pyruvate. HT-29 and C-32 cells were maintained in RPMI supplemented with 10% fetal calf serum and 2 mM L-glutamine. C57BL/6 and athymic nu/nu mice were purchased from Charles River Laboratories (Charles River Laboratories, Boston, MA). All animal studies were performed using an IACUC-approved protocol, and the work was performed under the guidelines established by Wake Forest University. The cells were grown to confluency, harvested, washed with phosphate-buffered saline and then were suspended in a 1:1 mixture of phosphate-buffered saline and Matrigel (BD Life Sciences, San Jose, CA) at a concentration of 5 × 106 cells/mL. For subcutaneous tumor xenografts, 6 mice were inoculated/6 mice were inoculated in the right flank with 100 μL of a suspension of B16F1 cells, and female athymic nu/nu mice were injected in the right flank with 100 μL of HT-29 cells or C-32 cells.
Preparation of 1-fluoro 2-tolunesulphonyloxyethane
To a solution of 2-fluoroethanol (480 mg, 7.52 mmol) in dry dichloromethane (100 mL) were successively added p-toluenesulfonyl chloride (2.16 g, 11.28 mmol), triethylamine (1.6 mL, 11.28 mmol), and 4-dimethylaminopyridine (108 mg, 0.88 mmol). After stirring the reaction mixture for 8 h at room temperature, the contents were washed with 1 M HCl (50 mL) and water (2 × 50 mL). The organic layer was separated, dried over anhydrous magnesium sulfate, filtered and evaporated to dryness. The residue was purified by silica gel flash column chromatography (10% ethyl acetate in hexane).
Preparation of N-(2-diethylaminoethyl) 4-hydroxybenzamide (4-HBZA; 1)
This intermediate was synthesized as described previously . Briefly, a mixture of thionyl chloride (30 mL) and 4-acetoxy benzoic acid (7.4 g, 43 mmol) in dimethylformamide (5 mL) was refluxed for 4 h. After removal of thionyl chloride on a rotary evaporator, triethylamine (6 mL, 43 mmol) and N,N-diethylethylenediamine (5 g, 43 mmol) were added slowly at 0 °C, and the contents were stirred overnight at room temperature. After the usual work-up of the reaction, 50 mL of sodium methoxide in methanol (0.5 M) was added followed by stirring the reaction mixture for 24 h at room temperature. After evaporating the solvent, the residue was dissolved in 200 mL of dichloromethane and was washed successively with water (2 × 50 mL), 1 M sodium bicarbonate (2 × 20 mL), and water (2 × 100 mL). The resulting crude product was purified using silica gel flash column chromatography (5% methanol in dichloromethane).
Preparation of N-(2-diethylaminoethyl) 4-(2-tolunesulphonyloxyethoxy) benzamide (3)
A suspension of NaH (120 mg, 5 mmol) in tetrahydrofuran (THF) (50 mL) was cooled to 0 °C, and a solution of 4-HBZA (1) (590 mg, 2.5 mmol) in 20 mL of THF was added. After stirring the reaction mixture for 10 min, a solution of 1,2-di-toluenesulphonyloxyethane (1.85 g, 5 mmol) in 10 mL of THF was added, and the reaction mixture was refluxed overnight. The contents were extracted in 100 mL of dichloromethane, and the organic layer was washed with 1 M HCl followed by 2 × 50 mL of water. Dichloromethane was removed, and the residue was purified using flash column chromatography (5% methanol in CH2Cl2). The molecular formula was as follows: C22H30N2O5S. 1H NMR (CDCl3, δ). 1H NMR (CDCl3, δ): 1.33 (t, 6H, 2 × N–(CH2–CH 3)2), 2.36 (s, 3H, CH 3–Ar–SO2), 3.17 (q, 4H, 2 × N–(CH 2–CH3)2), 3.33 (t, 2H, −CH 2–N–(CH2–CH3)2), 3.82 (m, 2H, −CONH–CH 2–), 4.12 (m, 2H, Ar–O–CH 2–CH2–), 4.36 (m, 2H, Ar–O–CH2–CH 2–), 7.17 (m, 2H, Ar–H–C3 and C5–), 7.27 (m, 2H, Ar–H–C2 and C6). ESI-MS m/z [MH]+ calcd 434, found 435.19.
Preparation of N-(2-diethylaminoethyl) 4-fluoroethoxybenzamide (4-FEBZA; 2)
A suspension of NaH (120 mg, 5 mmol) in tetrahydrofuran (50 mL) was cooled to 0 °C, and a solution of 4-HBZA (590 mg, 2.5 mmol) in tetrahydrofuran (20 mL) was added. After stirring the reaction mixture for 10 min, a solution of 1-fluoro-2-tosyloxyethane (1.09 g, 5 mmol) in 10 mL of tetrahydrofuran was added, and the reaction mixture was refluxed overnight. After adding 100 mL of dichloromethane, the contents were washed with 1 M HCl followed with 2 × 50 mL of water. After drying the organic layer over anhydrous magnesium sulfate, the solvent was removed, and the residue was purified using flash column chromatography (5% methanol in CH2Cl2) to afford the desired product. The molecular formula was as follows: C15H23N2O2F. 1H NMR (CDCl3, δ): 1.07 (t, 6H, 2 × −CH2–CH 3), 2.61 (q, 4H, 2 × −CH 2 CH3), 2.70 (t, 2H, −CH 2–N–(CH2–CH3)2), 3.50 (q, 2H, −CONH–CH2–), 4.25 (m, 2H, F–CH2–CH 2), 4.78 (m 2H F–CH 2–CH2), 6.95 (m, 2H, Ar–H–C3 and C5–), 7.78 (m, 2H, Ar–H–C2 and C6). ESI-MS m/z [MH]+ calcd 282; found 283.29.
Radiochemical synthesis of N-(2-diethylaminoethyl) 4-[18F]fluoroethoxybenzamide (4-[18F]FEBZA; 4)
After irradiation, the 18O–H2O bolus containing 450–800 mCi of [18F]fluoride was transferred from the cyclotron target to a pre-activated QMA cartridge in the hot cell. The trapped [18F]fluoride was eluted from the cartridge with 1.5 mL of kryptofix (K2.2.2.) solution prepared as described previously . The remaining water from this mixture was removed azeotropically using acetonitrile. The dried [18F]fluoride thus obtained was reacted with a freshly prepared solution of 1–5 mg of precursor 3 in 200 μL of anhydrous DMSO or acetonitrile at 115 °C for 5–20 min. Subsequently, the contents were diluted with 1 mL of water and loaded on to a reverse phase semi-preparatory HPLC column. The product was eluted from the column into a flask containing 70 mL of water. Subsequently, the contents were transferred and trapped onto a C-18 Sep-Pak, and the cartridge was washed with 10 mL of water to remove solvent residue. The desired product was eluted from the Sep-Pak with 1 mL of ethanol followed by 9 mL of saline and collection in a sterile product vial.
In vitro binding assay
The binding affinity of 4-[18F]FEBZA was measured using the homologous completion assay in 12-well plates containing a uniform number of fixed B16F1 cells/well. After adding 0.1 nmol of 4-[18F]FEBZA/well as the radioligand, unlabeled 4-FEBZA (2) was added to the quadruplicate sets of wells in concentrations ranging from 10−11 to 10−4 M and the plates were incubated for an hour at 37 °C under 5% CO2. At the end of the incubation, the media were removed, and the cells were washed with 500 μL of ice-cold media. The cells were lysed using 1 mL of phosphate-buffered saline containing 10% Triton X-100, and the lysates were collected in culture tubes to measure the radioactivity contents using a γ-counter. We performed a non-linear regression analysis of the decay-corrected CPM values to calculate the inhibition constant value (IC50), the concentration of competitor required to inhibit 50% of radiotracer binding, utilizing the GraphPad Prism software program (GraphPad Software, Inc., CA). The binding curve was generated by fitting the data simultaneously to one-site and two-site competitive binding models, and the F test provided a preferred model for the mean IC50 values (confidence interval 95%).
The in vitro cell binding was assessed by growing B16F1 cells in culture flasks to 80–90% confluence, trypsinizing, washing in PBS (pH 7.4), aliquoting into 12-well plates and allowing adherence to the wells overnight. Initially, we studied the influence of the incubation time and temperature on the binding to B16F1 melanoma cells. For this study, 12-well plates containing ~2.5 × 105 cells/well were incubated at 0, 22, and 37 °C with 4-[18F]FEBZA in quadruplicate sets for 15, 30, 60, 120, and 180 min. After the incubation, the media were removed, and each well was washed with fresh ice-cold media (2 × 2 mL). The adherent cells were removed by lysing cells in 500 μL of PBS containing 10% Triton X-100 (Sigma-Aldrich, St. Louis, MO). The combined washes and lysate were analyzed for radioactivity content using a γ-counter.
Next, we evaluated the binding characteristics of 4-[18F]FEBZA to B16F1 cells through internalization experiments [33, 34]. The cells were treated with a low pH buffer to sequester membrane-bound radioactivity (acid wash-releasable) from the internalized (acid wash-resistant) fraction . For this assay, 4-[18F]FEBZA was added to 12-well plates with each well containing 4 × 105 B16F1cells/well (in quadruplicate), and the plates were incubated at 37 °C for 15, 30, 60, 120, and 180 min. After the incubation, the media were removed, each well was washed with ice-cold PBS (2 × 1 mL), and the washes were collected in the tubes. Subsequently, each well was gently treated with 1 mL of an ice-cold mildly acidic medium (sodium acetate buffer, pH 4.5) to remove surface-bound radioactivity, and the rinses were collected in tubes (acidic wash). The adherent cells were then lysed using 500 μL of 10% Triton X-100 in PBS, and the lysate was transferred into tubes. The total radioactivity in each of the lysate, acidic wash, and the PBS wash was measured using a γ-counter.
Tissue distribution studies
The biodistribution studies were performed in mice bearing B16F1 (1 h n = 5; 2 h n = 6), C-32 (1 h n = 3; 2 h n = 3), and HT-29 (1 h n = 3; 2 h n = 3) tumor xenografts. The tumor-bearing mice were injected with ~40 μCi of 4-[18F]FEBZA. A separate group of normal C57BL/6 mice with no tumor implants (1 h n = 3; 2 h n = 3) was also injected with ~40 μCi of 4-[18F]FEBZA to study the distribution characteristics of 4-[18F]FEBZA in the absence of tumors. At 1 h and 2 h post-injection, the mice were euthanized, and the tissues of interest were removed, rinsed with PBS, weighed, and counted for radioactivity contents using a γ-counter.
MicroPET imaging studies
In vivo imaging of 4-[18F]FEBZA in mice bearing B16F1 (n = 2) and HT-29 (n = 1) tumor was performed using a P4 microPET™ scanner (Concorde Microsystems, Inc., Knoxville, TN). After administering ~100 μCi of 4-[18F]FEBZA via tail-vein injection, whole body PET scans were acquired in list mode. The images were reconstructed using filtered back projection with attenuation correction. Regions Of Interest (ROIs) were drawn on select organs using the summed image from the entire scan acquisition session, and the data were analyzed using ASIPro software (Siemens Preclinical Solutions, Knoxville, TN). The time activity curves (TACs) were generated from the list mode data reconstructed into multiple 5-min frames.
Biodistribution of 4-[18F]FEBZA in mice bearing tumor xenografts
%IA/g tissue (mean ± SD)
(n = 6)
(n = 5)
(n = 3)
(n = 3)
(n = 3)
(n = 3)
3.25 ± 0.34
2.28 ± 0.49
4.84 ± 0.95
2.50 ± 0.29
3.11 ± 0.49
1.99 ± 0.12
2.24 ± 0.36
1.58 ± 0.18
2.11 ± 0.25
1.51 ± 0.12
1.96 ± 0.38
1.22 ± 0.08
2.12 ± 0.17
1.49 ± 0.49
2.19 ± 0.33
1.63 ± 0.16
1.94 ± 0.67
1.33 ± 0.35
2.82 ± 0.25
2.12 ± 0.58
2.52 ± 0.12
2.19 ± 0.37
2.52 ± 0.15
1.75 ± 0.35
3.10 ± 0.28
2.20 ± 0.38
2.91 ± 0.24
2.08 ± 0.29
2.85 ± 0.37
1.84 ± 0.12
3.78 ± 0.45
5.45 ± 0.98
3.83 ± 0.39
5.71 ± 1.11
3.47 ± 0.78
5.09 ± 0.72
2.49 ± 0.25
1.60 ± 0.31
1.98 ± 0.62
1.42 ± 0.10
2.23 ± 0.21
1.33 ± 0.06
2.48 ± 0.35
1.73 ± 0.14
2.41 ± 0.26
1.56 ± 0.18
2.49 ± 0.42
1.40 ± 0.10
1.51 ± 0.21
1.14 ± 0.21
1.61 ± 0.28
1.40 ± 0.24
2.35 ± 1.06
1.05 ± 0.14
2.55 ± 0.61
2.25 ± 0.50
1.68 ± 0.18
1.52 ± 0.28
1.87 ± 0.21
1.36 ± 0.17
1.10 ± 0.36
0.88 ± 0.06
1.07 ± 0.08
0.91 ± 0.19
1.26 ± 0.39
0.77 ± 0.18
3.06 ± 0.52
2.51 ± 0.93
2.80 ± 0.26
2.29 ± 0.23
3.22 ± 0.64
2.40 ± 0.30
8.66 ± 1.02
7.47 ± 1.34
3.68 ± 0.47
3.07 ± 0.36
3.91 ± 0.23
2.53 ± 0.19
Towards an ongoing effort to develop a PET imaging probe to target melanoma with high specificity and selectivity, we recently reported the synthesis and preliminary preclinical evaluations of a novel PET imaging probe 11C-MBZA. Despite its attractive in vitro binding and in vivo biodistribution characteristics, the short half-life of C-11 radionuclide (t 1/2 = 20 min) remained a small set-back for the wide use of this very promising probe. Our next goal was to develop an imaging probe incorporating a facile and rapid radiochemical synthesis along with biological traits similar 11C-MBZA. To that end, we have now developed an F-18-labeled fluoroethoxy analog, i.e., 4-[18F]FEBZA, and herein, we present those findings.
The radiosynthesis procedure for 4-[18F]FEBZA is quite simple and straight forward. This procedure provides the desired compound in high radiochemical yields and purity. The synthesis time and the radiochemical yields for the 4-[18F]FEBZA are quite comparable to those reported for many of the other melanoma-targeting agents reported earlier such as 18F-DAFBA , F-18-labeled iodoquinoxaline carboxamide , 18F-FPBZA , MEL050, and other F-18-labeled fluoronicotinamides . Additionally, the synthesis of 4-[18F]FEBZA is quite adaptable to automation using many of the commercially available synthesis modules.
4-[18F]FEBZA showed a rapid and high binding to B16F1 melanoma cells at 37 and 22 °C. In contrast, it showed insignificant binding to B16F1 cells at 0 °C; perhaps indicating the involvement of an active uptake pathway towards its binding to melanoma cells. In addition to temperature dependency, 4-[18F]FEBZA also showed a time-dependent increase in binding. A threefold higher binding was noted when the cells were incubated for 60 min as compared to a 15 min incubation. While the cell binding continued to further increase with time, the increase was modest beyond 120 min incubation. The increase in binding for cells incubated at 22 °C was slightly lower than that at 37 °C. For comparison, the overall binding of 18F-FPBZA to B16F0 melanoma cells was 4.12 ± 0.20% after 2 h incubation at 37 °C, a 20-fold lower binding despite a higher number of cells (1 × 106 cells) used in the assay .
A two- to threefold higher uptake of radioactivity was noted in B16F1 melanoma tumors as compared to that in the HT-29 or the amelanotic C-32 tumors. The 18F-FEBZA uptake in B16F1 tumor is quite similar to tumor uptake reported for various other fluorinated benzamides. For example, the F-18 uptake in B16F1 tumor at 1 h was 8.66 ± 1.02%IA/g, 8.4 ± 1.5%IA/g, and 8.31 ± 1.00%IA/g for the 18F-FEBZA, MEL050, and 18F-FPBZA, respectively [25, 26, 28, 35]. Similarly, the uptake of these three compounds in non-melanoma tumor was low.
The biodistribution studies show a low uptake of 4-[18F]FEBZA in normal tissue and the uptake levels continued to decrease further with time, leading to significantly reduced radioactivity levels in normal tissues. For example, the uptake in the liver and the lungs from B16F1 tumor-bearing mice at 1 h was 3.25 ± 0.34%IA/g and 2.12 ± 0.17%IA/g, respectively, and these levels decreased to 2.28 ± 0.49%IA/g and 1.49 ± 0.49%IAD/g, respectively, by 2 h. The radioactivity contents in the small intestine of mice bearing B16F1, HT-29, and C-32 tumors was 2.48 ± 0.35%IA/g, 1.98 ± 0.62%IA/g, and 2.23 ± 0.21%IA/g, respectively, at 1 h. Uptake in intestine seems high but radioactivity levels in intestine was comparable to uptake levels seen in other organs. The intestinal uptake for 18F-DAFBA, MEL050, and 18F-FPBZA at 1 h in mice bearing B16F melanoma tumor was 3.04 ± 0.24%IA/g, 2.1 ± 0.3%IA/g, and 2.45 ± 0.38%IA/g, respectively.
Additionally, the uptake levels in the liver, lungs, intestine, and several other organs were comparable between the three types of tumor-bearing mice used in this study. For a radiotracer to qualify as good imaging agent, it should exhibit low uptake in normal tissues along with a rapid and high uptake in the tumor. A high lipophilicity of the compound has been identified as one of the many factors responsible for higher uptake in normal tissues. Therefore, a radiotracer with lower lipophilicity would be desirable to minimize accumulation in the normal tissues, but could alongside, has the potential to reduce its uptake in the tumor. Therefore, a good balance between lipophilicity and functional groups within the molecular moiety is a key when designing biologically active imaging agents.
A low uptake of radioactivity was noted in most normal tissues except for the bones. A high uptake in the bones is generally an indirect measure of in vivo defluorination [25, 36, 37], thus indicating metabolic dehalogenation of 4-[18F]FEBZA. Although high bone uptake has been reported for MEL050 (0.58 ± 0.05%IA/g at 2 h) and 18F-FPBZA (3.21 ± 0.16%IA/g at 2 h), high bone uptake observed for the 18F-FEBZA is somewhat unexpected since the structurally close analog 18F-DAFBA showed low bone uptake (0.20 ± 0.06%IA/g at 2 h) . Placement of fluorine group on the alkyl chain of 4-[18F]FEBZA may be a likely contributor towards enhanced defluorination. The covalently bound fluorine to aryl group in 18F-DAFBA and MEL050 may have provided extra stability to Aryl–F bond towards catabolic defluorination in vivo. To further investigate whether the enhanced defluorination of 18F-FEBZA and subsequent accumulation of 18F-fluoride in the bone was tumor mediated phenomenon, we repeated the biodistribution study in C57BL/6 mice with no implanted tumor. The bone uptake at 1 h in mice with no tumor, and the mice with B16F1, HT-29, and C-32 tumors was 3.23 ± 0.24%IA/g, 3.78 ± 0.45%IA/g, 3.83 ± 0.39%IA/g, and 3.47 ± 0.78%IA/g, respectively (p > 0.1). In addition, the uptake of 4-[18F]FEBZA in various organs was similar in mice with no tumors and the tumor bearing mice. For example, at 1 h %IA/g in the liver, lungs, muscle, blood, and brain was 3.25 ± 0.34, 2.12 ± 0.17, 1.51 ± 0.21, 3.06 ± 0.52, and 2.55 ± 0.61, respectively, in mice bearing B16F1 tumor (Table 1) and 4.11 ± 0.63, 2.52 ± 0.47, 1.10 ± 0.13, 2.81 ± 0.31, and 2.46 ± 0.41, respectively, in mice without the implanted tumor. The differences in tissue uptake for the two groups are statistically insignificant (p > 0.1). Similarity in tissue distribution data and bone uptake levels for the two groups of mice indicate that the defluorination might be resulting from weaker C–F alkyl bond and perhaps not due to tumor mediated catabolic defluorination of the parent molecule.
The ability of a melanoma imaging agent to cross the blood brain barrier is considered another important feature of probes to target metastatic lesions to the brain. The tissue distribution studies showed a modest uptake of radioactivity in the mouse brain (2.55 ± 0.61%IA/g at 1 h) demonstrating the ability of this compound to cross the blood-brain barrier. In comparison, the uptake of MEL050 in mouse brain as determined from microPET imaging studies was 1.38 ± 0.40%IA/g at 60–70 min . More importantly, the levels in the brain were significantly lower than those in the tumor. The tumor-to-brain tissue ratios for the B16F1 and HT-29 groups were 3.55 ± 0.80 and 2.19 ± 0.04, respectively, at 1 h, and 3.45 ± 0.81 and 2.04 ± 0.19, respectively, at 2 h. A high tumor-to-brain ratio (Fig. 6) further supports the ability of 4-[18F]FEBZA to delineate metastatic lesions present in the brain.
On these reconstructed images, the B16F1 tumor is clearly visible as early as 10 min post-injection and the uptake intensity continued to increase with time. In addition, a characteristic uptake in the eyes is also distinctly visible in images at all time points.
In summary, 4-[18F]FEBZA shows a selective and rapid uptake by melanoma cells in vitro. Preferential uptake in melanoma tumor xenograft along with a favorable whole body distribution pattern in vivo suggests a significant potential of this radiotracer in delineating and localizing melanoma.
Herein, we have developed a rapid and reliable one-step synthesis of 4-[18F]FEBZA that provides the desired product in high radiochemical yields and high specific activity. The in vitro studies show a high binding affinity of this compound to melanoma cells. The biodistribution and microPET imaging studies show a rapid and preferential accumulation of 4-[18F]FEBZA in melanoma tumors. Results from these preclinical studies suggests that 4-[18F]FEBZA is a promising PET imaging probe to target melanoma.
We would like to thank Kimberly Black, Holly Smith, Leah Rutkowski, and Li Wu for their excellent technical help. A strong support from the Center for Biomolecular Imaging is greatly appreciated and acknowledged.
The manuscript was written by PKG. The Chemistry and radiochemistry was designed and performed by RN and SG. The in vitro assays and cell binding assays were conducted by VG. The microPET data was analyzed by YW. In general, all the experiments were designed by PKG and SG, and these experiments were executed under PG guidance. All authors read and approved the final manuscript.
This manuscript does not include human studies. All studies that involved the use of animals were performed under IACUC-approved protocol (Institutional Animal Care and Use Committee) and the work was performed following the guidelines established by the Wake Forest University.
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67:7–30.View ArticlePubMedGoogle Scholar
- Trinh VA. Current management of metastatic melanoma. Am J Health Syst Pharm. 2008;65:S3–8.View ArticlePubMedGoogle Scholar
- Jost LM. ESMO Minimum Clinical Recommendations for diagnosis, treatment and follow-up of cutaneous malignant melanoma. Ann Oncol. 2003;14:1012–3.View ArticlePubMedGoogle Scholar
- Strauss LG, Conti PS. The applications of PET in clinical oncology. J Nucl Med. 1991;32:623–48. discussion 649-650PubMedGoogle Scholar
- Hawkins RA, Hoh C, Glaspy J, Rege S, Choi Y, Phelps ME. Positron emission tomography scanning in cancer. Cancer Investig. 1994;12:74–87.View ArticleGoogle Scholar
- Wagner JD, Schauwecker D, Davidson D, et al. Inefficacy of F-18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma. Cancer. 2005;104:570–9.View ArticlePubMedGoogle Scholar
- Havenga K, Cobben DC, Oyen WJ, et al. Fluorodeoxyglucose-positron emission tomography and sentinel lymph node biopsy in staging primary cutaneous melanoma. Eur J Surg Oncol. 2003;29:662–4.View ArticlePubMedGoogle Scholar
- Longo MI, Lazaro P, Bueno C, Carreras JL, Montz R. Fluorodeoxyglucose-positron emission tomography imaging versus sentinel node biopsy in the primary staging of melanoma patients. Dermatol Surg. 2003;29:245–8.PubMedGoogle Scholar
- Wagner JD, Schauwecker D, Davidson D, et al. Prospective study of fluorodeoxyglucose-positron emission tomography imaging of lymph node basins in melanoma patients undergoing sentinel node biopsy. J Clin Oncol. 1999;17:1508–15.View ArticlePubMedGoogle Scholar
- Belhocine T, Pierard G, De Labrassinne M, Lahaye T, Rigo P. Staging of regional nodes in AJCC stage I and II melanoma: 18FDG PET imaging versus sentinel node detection. Oncologist. 2002;7:271–8.View ArticlePubMedGoogle Scholar
- Acland KM, Healy C, Calonje E, et al. Comparison of positron emission tomography scanning and sentinel node biopsy in the detection of micrometastases of primary cutaneous malignant melanoma. J Clin Oncol. 2001;19:2674–8.View ArticlePubMedGoogle Scholar
- Macapinlac HA. The utility of 2-deoxy-2-[18F]fluoro-D-glucose-positron emission tomography and combined positron emission tomography and computed tomography in lymphoma and melanoma. Mol Imaging Biol. 2004;6:200–7.View ArticlePubMedGoogle Scholar
- Decristoforo C, Hernandez Gonzalez I, Carlsen J, et al. 68Ga- and 111In-labelled DOTA-RGD peptides for imaging of alphavbeta3 integrin expression. Eur J Nucl Med Mol Imaging. 2008;35:1507–15.View ArticlePubMedGoogle Scholar
- Cheng Z, Zhang L, Graves E, et al. Small-animal PET of melanocortin 1 receptor expression using a 18F-labeled alpha-melanocyte-stimulating hormone analog. J Nucl Med. 2007;48:987–94.View ArticlePubMedPubMed CentralGoogle Scholar
- Garg S, Kothari K, Thopate S, et al. N-(2-diethylaminoethyl)-4-[18F]fluorobenzamide (DAFBA): a promising PET ligand to image melanoma. J Label Comp Radiopharm. 2007;50:S196.Google Scholar
- Cheng Z, Xiong Z, Subbarayan M, Chen X, Gambhir SS. 64Cu-labeled alpha-melanocyte-stimulating hormone analog for microPET imaging of melanocortin 1 receptor expression. Bioconjug Chem. 2007;18:765–72.View ArticlePubMedPubMed CentralGoogle Scholar
- Ren G, Liu Z, Miao Z, et al. PET of malignant melanoma using 18F-labeled metallopeptides. J Nucl Med. 2009;50:1865–72.View ArticlePubMedPubMed CentralGoogle Scholar
- Vaidyanathan G, Zalutsky MR. Fluorine-18-labeled [Nle4,D-Phe7]-alpha-MSH, an alpha-melanocyte stimulating hormone analogue. Nucl Med Biol. 1997;24:171–8.View ArticlePubMedGoogle Scholar
- Wei L, Butcher C, Miao Y, et al. Synthesis and biologic evaluation of 64Cu-labeled rhenium-cyclized alpha-MSH peptide analog using a cross-bridged cyclam chelator. J Nucl Med. 2007;48:64–72.PubMedGoogle Scholar
- Billaud EM, Rbah-Vidal L, Vidal A, et al. Synthesis, radiofluorination, and in vivo evaluation of novel fluorinated and iodinated radiotracers for PET imaging and targeted radionuclide therapy of melanoma. J Med Chem. 2013;56:8455–67.View ArticlePubMedGoogle Scholar
- Eisenhut M, Hull WE, Mohammed A, et al. Radioiodinated N-(2-diethylaminoethyl)benzamide derivatives with high melanoma uptake: structure-affinity relationships, metabolic fate, and intracellular localization. J Med Chem. 2000;43:3913–22.View ArticlePubMedGoogle Scholar
- Chezal JM, Papon J, Labarre P, et al. Evaluation of radiolabeled (hetero)aromatic analogues of N-(2-diethylaminoethyl)-4-iodobenzamide for imaging and targeted radionuclide therapy of melanoma. J Med Chem. 2008;51:3133–44.View ArticlePubMedGoogle Scholar
- Moins N, Papon J, Seguin H, et al. Synthesis, characterization and comparative biodistribution study of a new series of p-iodine-125 benzamides as potential melanoma imaging agents. Nucl Med Biol. 2001;28:799–808.View ArticlePubMedGoogle Scholar
- Michelot JM, Moreau MF, Labarre PG, et al. Synthesis and evaluation of new iodine-125 radiopharmaceuticals as potential tracers for malignant melanoma. J Nucl Med. 1991;32:1573–80.PubMedGoogle Scholar
- Garg S, Kothari K, Thopate SR, Doke AK, Garg PK. Design, synthesis, and preliminary in vitro and in vivo evaluation of N-(2-diethylaminoethyl)-4-[(18)F]fluorobenzamide ([(18)F]-DAFBA): a novel potential PET probe to image melanoma tumors. Bioconjug Chem. 2009;20:583–90.View ArticlePubMedPubMed CentralGoogle Scholar
- Ren G, Miao Z, Liu H, et al. Melanin-targeted preclinical PET imaging of melanoma metastasis. J Nucl Med. 2009;50:1692–9.View ArticlePubMedPubMed CentralGoogle Scholar
- Greguric I, Taylor SR, Denoyer D, et al. Discovery of [18F]N-(2-(diethylamino)ethyl)-6-fluoronicotinamide: a melanoma positron emission tomography imaging radiotracer with high tumor to body contrast ratio and rapid renal clearance. J Med Chem. 2009;52:5299–302.View ArticlePubMedGoogle Scholar
- Wu SY, Huang SP, Lo YC, et al. Synthesis and preclinical characterization of [18F]FPBZA: a novel PET probe for melanoma. Biomed Res Int. 2014;2014:912498.PubMedPubMed CentralGoogle Scholar
- Feng H, Xia X, Li C, et al. Imaging malignant melanoma with (18)F-5-FPN. Eur J Nucl Med Mol Imaging. 2016;43:113–22.View ArticlePubMedGoogle Scholar
- Liu H, Liu S, Miao Z, et al. A novel aliphatic 18F-labeled probe for PET imaging of melanoma. Mol Pharm. 2013;10:3384–91.View ArticlePubMedPubMed CentralGoogle Scholar
- Garg PK, Nazih R, Wu Y, Singh RA, Garg S. 4-[11C]Methoxy N-(2-diethylaminoethyl) benzamide: a novel probe to selectively target melanoma. J Nucl Med. 2017;58:827–32.Google Scholar
- Garg S, Lynch AJ, Doke AK, Minton RC, Garg PK. A remote controlled system for the preparation of 7alpha-[(18)F]fluoro-17alpha-methyl 5alpha-dihydrotestosterone ([(18)F]FMDHT) using microwave. Appl Radiat Isot. 2008;66:612–8.View ArticlePubMedPubMed CentralGoogle Scholar
- Bergmann R, Scheunemann M, Heichert C, et al. Biodistribution and catabolism of (18)F-labeled neurotensin(8-13) analogs. Nucl Med Biol. 2002;29:61–72.View ArticlePubMedGoogle Scholar
- Hofland LJ, van Koetsveld PM, Waaijers M, Zuyderwijk J, Breeman WA, Lamberts SW. Internalization of the radioiodinated somatostatin analog [125I-Tyr3]octreotide by mouse and human pituitary tumor cells: increase by unlabeled octreotide. Endocrinology. 1995;136:3698–706.View ArticlePubMedGoogle Scholar
- Denoyer D, Greguric I, Roselt P, et al. High-contrast PET of melanoma using (18)F-MEL050, a selective probe for melanin with predominantly renal clearance. J Nucl Med. 2010;51:441–7.View ArticlePubMedGoogle Scholar
- Terry GE, Hirvonen J, Liow JS, et al. Imaging and quantitation of cannabinoid CB1 receptors in human and monkey brains using (18)F-labeled inverse agonist radioligands. J Nucl Med. 2010;51:112–20.View ArticlePubMedGoogle Scholar
- Grant FD, Fahey FH, Packard AB, Davis RT, Alavi A, Treves ST. Skeletal PET with 18F-fluoride: applying new technology to an old tracer. J Nucl Med. 2008;49:68–78.View ArticlePubMedGoogle Scholar
- Rizzo-Padoin N, Chaussard M, Vignal N, et al. [18F]MEL050 as a melanin-targeted PET tracer: Fully automated radiosynthesis and comparison to 18F-FDG for the detection of pigmented melanoma in mice primary subcutaneous tumors and pulmonary metastases. Nucl Med Biol. 2016;43:773–80.View ArticlePubMedGoogle Scholar
- Pham TQ, Greguric I, Liu X, et al. Synthesis and evaluation of novel radioiodinated benzamides for malignant melanoma. J Med Chem. 2007;50:3561–72.View ArticlePubMedGoogle Scholar